Vistagen Therapeutics Inc (VTGN) FinancialsVTGNVistagen Therapeutics Inc

Evaluating the bottom line, Vistagen Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -904.34%, while the net margin is -882.79%. These profitability ratios, combined with a Return on Equity (ROE) of -166.46%, provide a clear picture of how effectively VTGN converts its operational activities into shareholder value.

In the context of the broader market, VTGN competes directly with industry leaders such as MTVA and GDTC. With a market capitalization of $11.22M, it holds a significant position in the sector. When comparing efficiency, VTGN's gross margin of N/A stands against MTVA's N/A and GDTC's 32.69%. Such benchmarking helps identify whether Vistagen Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Vistagen's revenue has shown a year-over-year increase of 164.6%, reaching $1.27 million, but the company still reported a net loss of $13 million for Q1 FY2027. Gross margins remain high at 100%, but the overall financial health is concerning due to ongoing losses.